神経変性治療薬市場：薬剤クラス別、適応症別、販売チャネル別-2025-2030年の世界予測

神経変性治療薬市場は、2023年に418億4,000万米ドルと評価され、2024年には459億1,000万米ドルに達すると予測され、CAGR 8.67％で成長し、2030年には749億3,000万米ドルに達すると予測されています。

神経変性治療薬市場には、アルツハイマー病、パーキンソン病、多発性硬化症など、神経細胞の進行性変性を特徴とする疾患の治療を目的とする医薬品が含まれます。このような病気に罹患しやすい世界人口の高齢化と、症状を緩和し、理想的には根本的な原因に対処できる解決策に対する切実な需要を考えると、これらの医薬品に対する切実な必要性があります。これらの医薬品は、病院、診療所、革新的な神経学的治療法に携わる研究機関などのヘルスケア環境で主に使用されます。最終用途の範囲は、患者の直接治療から次世代治療法の調査支援にまで及ぶ。市場開拓に影響を与える主な要因としては、バイオテクノロジーの発展、神経変性疾患の罹患率の増加、研究開発への投資の増加などが挙げられます。さらに、個別化医療と遺伝子研究の台頭は、強力な成長手段を提供します。潜在的なビジネスチャンスは、疾患の進行に大きな影響を与える疾患修飾療法の開発にあり、これにより大きな市場シェアを獲得することができます。しかし、課題としては、薬剤開発コストの高さ、規制環境の厳しさ、疾病メカニズムの理解の浅さなどが挙げられます。また、市場成長の妨げとなっているのは、承認プロセスの遅さと、これらの薬剤の潜在的な副作用です。イノベーション分野の開拓には、早期発見のためのバイオマーカー、創薬におけるAIの活用、ナノテクノロジーのようなドラッグデリバリーシステムの開発などが適しています。さらに、製薬会社と研究機関のパートナーシップは、イノベーションと市場浸透を促進することができます。市場は本質的にダイナミックであり、急速な進歩と大手製薬企業や新興企業間の高い競争が特徴です。研究への継続的な投資と戦略的な提携は、競争力を高めることができます。神経変性治療薬市場の持続的成長には、革新的な画期的開発と規制・経済的ハードルへの対応とのバランスを保つことが重要です。

市場力学：急速に進化する神経変性治療薬市場の主要市場インサイトを公開

神経変性治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 神経疾患に対する意識の高まりと早期診断・治療の必要性
  • 医療アクセス向上のためのヘルスケア分野への投資の増加
• 市場抑制要因
  • 神経変性治療に伴う複雑さとリスク
• 市場機会
  • 神経変性治療薬に関する継続的な研究開発活動
  • 規制当局による医薬品承認の増加
• 市場の課題
  • 神経変性治療薬の摂取に伴う重篤な副作用

ポーターの5つの力：神経変性治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、神経変性治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経変性治療薬市場における外部からの影響の把握

外部マクロ環境要因は、神経変性治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析神経変性治療薬市場における競合情勢の把握

神経変性治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス神経変性治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経変性治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨神経変性治療薬市場における成功への道筋を描く

神経変性治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 神経疾患に対する意識の高まりと早期診断と治療の必要性
    • ヘルスケアへのアクセス向上のためヘルスケア分野への投資を増やす
  • 抑制要因
    • 神経変性治療に伴う複雑さとリスク
  • 機会
    • 神経変性治療薬に関する進行中の研究開発活動
    • 規制当局による医薬品承認件数の増加
  • 課題
    • 神経変性治療薬の摂取に伴う重篤な副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 神経変性治療薬市場薬剤クラス別

• コリンエステラーゼ阻害剤
• 脱炭酸酵素阻害剤
• ドーパミン作動薬
• 免疫調節薬

第7章 神経変性治療薬市場適応症別

• アルツハイマー病
• 痴呆
• ハンチントン病
• 運動ニューロン疾患
• パーキンソン病
• プリオン病
• 脊髄性筋萎縮症

第8章 神経変性治療薬市場：販売チャネル別

• オフライン
  • 病院薬局
  • 小売薬局
• オンライン

第9章 南北アメリカの神経変性治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の神経変性治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの神経変性治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• ACADIA Pharmaceuticals Inc.
• Amneal Pharmaceuticals, Inc.
• Aquinnah Pharmaceuticals
• AstraZeneca PLC
• AZTherapies, Inc.
• Bausch Health Companies Inc.
• Biogen Inc.
• Boehringer Ingelheim International GmbH
• Denali Therapeutics Inc.
• GlaxoSmithKline PLC
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Kyowa Kirin International plc
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Orion Corporation
• Pfizer, Inc.
• Prevail Therapeutics Inc. by Eli Lilly and Company
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Theravance Biopharma
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. NEURODEGENERATIVE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. NEURODEGENERATIVE DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEURODEGENERATIVE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEURODEGENERATIVE DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MOTOR NEURONE DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRION DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. INDIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. ITALY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. POLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. QATAR NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
• TABLE 194. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Neurodegenerative Drugs Market was valued at USD 41.84 billion in 2023, expected to reach USD 45.91 billion in 2024, and is projected to grow at a CAGR of 8.67%, to USD 74.93 billion by 2030.

The neurodegenerative drugs market encompasses pharmaceuticals that aim to treat diseases characterized by the progressive degeneration of nerve cells, such as Alzheimer's, Parkinson's, and multiple sclerosis. There is a compelling necessity for these drugs given the aging global population, which is highly susceptible to such ailments, and the existential demand for solutions that can alleviate symptoms or, ideally, address underlying causes. These drugs find their primary applications in healthcare settings such as hospitals, clinics, and research institutions engaged in innovative neurological therapeutics. Their end-use scope extends from direct patient care to aiding in research for next-generation therapies. Key factors that influence market growth include advances in biotechnology, increasing incidence rates of neurodegenerative diseases, and growing investments in research and development. Additionally, the rise of personalized medicine and genetic research offer potent growth avenues. Potential opportunities lie in the development of disease-modifying therapies which can significantly impact disease progression, thus capturing a significant market share. However, challenges stem from the high costs of drug development, stringent regulatory environments, and a limited understanding of disease mechanisms. Market growth is also impeded by the slow approval processes and potential adverse effects of these drugs. Innovation sectors ripe for exploration include biomarkers for early detection, utilization of AI in drug discovery, and development of drug delivery systems like nanotechnology. Moreover, partnerships between pharmaceutical companies and research institutions can drive innovation and market penetration. The market is inherently dynamic, characterized by rapid advancements and high competition among leading pharmaceutical giants and startups alike. Continuous investment in research, along with strategic collaborations, can provide a competitive edge. Maintaining a balance between innovative breakthrough developments and addressing regulatory and economic hurdles will be crucial for sustained growth in the neurodegenerative drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurodegenerative Drugs Market

The Neurodegenerative Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising awareness about neurological disorders and need of early diagnosis & treatment
  • Increasing investment in healthcare sector to improve healthcare accessibility
• Market Restraints
  • Complexities & risk associated with the neurodegenerative treatment
• Market Opportunities
  • Ongoing research & development activities for neurodegenerative drugs
  • Increasing number of drug approval by regulatory authorities
• Market Challenges
  • Severe side effects associated with the consumption of neurodegenerative drugs

Porter's Five Forces: A Strategic Tool for Navigating the Neurodegenerative Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurodegenerative Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurodegenerative Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurodegenerative Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurodegenerative Drugs Market

A detailed market share analysis in the Neurodegenerative Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurodegenerative Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurodegenerative Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurodegenerative Drugs Market

A strategic analysis of the Neurodegenerative Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurodegenerative Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACADIA Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Aquinnah Pharmaceuticals, AstraZeneca PLC, AZTherapies, Inc., Bausch Health Companies Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer, Inc., Prevail Therapeutics Inc. by Eli Lilly and Company, Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Neurodegenerative Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Cholinesterase Inhibitors, Decarboxylase Inhibitors, Dopamine Agonist, and Immunomodulators.
• Based on Indication, market is studied across Alzheimer's Disease, Dementia, Huntington's Disease, Motor Neurone Disease, Parkinson's Disease, Prion Disease, and Spinal Muscular Atrophy.
• Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising awareness about neurological disorders and need of early diagnosis & treatment
    • 5.1.1.2. Increasing investment in healthcare sector to improve healthcare accessibility
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities & risk associated with the neurodegenerative treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research & development activities for neurodegenerative drugs
    • 5.1.3.2. Increasing number of drug approval by regulatory authorities
  • 5.1.4. Challenges
    • 5.1.4.1. Severe side effects associated with the consumption of neurodegenerative drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neurodegenerative Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Cholinesterase Inhibitors
• 6.3. Decarboxylase Inhibitors
• 6.4. Dopamine Agonist
• 6.5. Immunomodulators

7. Neurodegenerative Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Alzheimer's Disease
• 7.3. Dementia
• 7.4. Huntington's Disease
• 7.5. Motor Neurone Disease
• 7.6. Parkinson's Disease
• 7.7. Prion Disease
• 7.8. Spinal Muscular Atrophy

8. Neurodegenerative Drugs Market, by Sales Channel

• 8.1. Introduction
• 8.2. Offline
  • 8.2.1. Hospitals Pharmacies
  • 8.2.2. Retail Pharmacies
• 8.3. Online

9. Americas Neurodegenerative Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Neurodegenerative Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Neurodegenerative Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. ACADIA Pharmaceuticals Inc.
• 4. Amneal Pharmaceuticals, Inc.
• 5. Aquinnah Pharmaceuticals
• 6. AstraZeneca PLC
• 7. AZTherapies, Inc.
• 8. Bausch Health Companies Inc.
• 9. Biogen Inc.
• 10. Boehringer Ingelheim International GmbH
• 11. Denali Therapeutics Inc.
• 12. GlaxoSmithKline PLC
• 13. H. Lundbeck A/S
• 14. Johnson & Johnson Services, Inc.
• 15. Kyowa Kirin International plc
• 16. Lupin Limited
• 17. Merck & Co., Inc.
• 18. Novartis AG
• 19. Orion Corporation
• 20. Pfizer, Inc.
• 21. Prevail Therapeutics Inc. by Eli Lilly and Company
• 22. Sanofi S.A.
• 23. Takeda Pharmaceutical Company Limited
• 24. Theravance Biopharma
• 25. UCB S.A.